Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013492 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Yuan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Coronavirus OC43, Human, Chalcones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Plan of China, National Natural Science Foundation of China, Major Project of Guangzhou National Laboratory.
Abstract (Originalsprache)
Coronavirus, a large family of positive-sense RNA viruses, are responsible for both mild and severe respiratory illnesses, ranging from the common cold to life-threatening conditions. Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed to address both current and future HCoV outbreaks. Here, we conducted high-throughput screening of a natural product library containing 3407 compounds to identify potential antiviral agents against HCoV-OC43 and HCoV-229E. We identified several natural products with inhibitory effects on HCoV-229E, HCoV-OC43, and the SARS-CoV-2 variants Delta (B.1.617.2) and Omicron (BA.5) in vitro without evident cytotoxicity. Among these, dibenzoylmethane (DBM) not only demonstrated broad-spectrum anticoronavirus activity in vitro but also effectively inhibited HCoV-OC43 replication in a BALB/c mouse model. Pharmacokinetic analysis revealed that DBM, when administered orally, maintained effective concentrations in the blood over an extended period, suggesting its suitability for oral administration. Mechanistically, DBM was found to regulate caspase-6, a host factor that suppresses interferon signalling and promotes HCoV replication. These findings highlight DBM as a promising candidate for the development of therapeutics targeting HCoVs, offering potential for treating infections by both established and emerging HCoVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Hubei Jiangxia Laboratory, Wuhan, China.
ORCID-Profile: Yumin Zhang
Förderung
- National Key Research and Development Plan of China
- National Natural Science Foundation of China
- Major Project of Guangzhou National Laboratory
- Hubei Natural Science Foundation for Distinguished Young Scholars
- Key R&D Program of Hubei Province
Zitieren
APA
Sun, Y., Shu, X., Chen, L., Shang, W., Zhang, Y., Xiao, G., & Zhang, L. (2025). Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013492
Vancouver
Sun Y, Shu X, Chen L, Shang W, Zhang Y, Xiao G, et al. Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013492
BibTeX
@article{Sun2025,
author = {Sun, Yuan and Shu, Xiaoyang and Chen, Lu and Shang, Weijuan and Zhang, Yumin and Xiao, Gengfu and Zhang, Leike},
title = {Discovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013492}
}
EUVIMED